Anti-Cancer Effects of Zotarolimus Combined with 5-Fluorouracil Treatment in HCT-116 Colorectal Cancer-Bearing BALB/c Nude Mice

Geng-Ruei Chang,Chan-Yen Kuo,Ming-Yang Tsai,Wei-Li Lin,Tzu-Chun Lin,Huei-Jyuan Liao,Chung-Hung Chen,Yu-Chen Wang

DOI: https://doi.org/10.3390/molecules26154683

IF: 4.6

2021-08-02

Molecules

Abstract:Zotarolimus is a semi-synthetic derivative of rapamycin and an inhibitor of mammalian target of rapamycin (mTOR) signaling. Currently, zotarolimus is used to prolong the survival time of organ grafts, but it is also a novel immunosuppressive agent with potent anti-proliferative activity. Here, we examine the anti-tumor effect of zotarolimus, alone and in combination with 5-fluorouracil, on HCT-116 colorectal adenocarcinoma cells implanted in BALB/c nude mice. Compared with the control mice, mice treated with zotarolimus or zotarolimus combined with 5-FU showed retarded tumor growth; increased tumor apoptosis through the enhanced expression of cleaved caspase 3 and extracellular signal-regulated kinase (ERK) phosphorylation; reduced inflammation-related factors such as IL-1β, TNF-α, and cyclooxygenase-2 (COX-2) protein; and inhibited metastasis-related factors such as CD44, epidermal growth factor receptor (EGFR), transforming growth factor β (TGF-β), and vascular endothelial growth factor (VEGF). Notably, mice treated with a combination of zotarolimus and 5-FU showed significantly retarded tumor growth, reduced tumor size, and increased tumor inhibition compared with mice treated with 5-FU or zotarolimus alone, indicating a strong synergistic effect. This in vivo study confirms that zotarolimus or zotarolimus combined with 5-FU can be used to retard colorectal adenocarcinoma growth and inhibit tumorigenesis. Our results suggest that zotarolimus may increase the chemo-sensitization of tumor cells. Therefore, zotarolimus alone and zotarolimus combined with 5-FU may be potential anti-tumor agents in the treatment of human colon adenocarcinoma. Future research on zotarolimus may lead to the development of new therapeutic strategies.

chemistry, multidisciplinary,biochemistry & molecular biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the anticancer effects of zotarolimus used alone or in combination with 5 - Fluorouracil (5 - FU) on human colon adenocarcinoma HCT - 116 cells in the BALB/c nude mouse model. Specifically, the study aims to evaluate whether zotarolimus can inhibit tumor growth in the following ways:

1. **Slowing down tumor growth**: The effect of the drug is evaluated by observing the changes in tumor volume between the treatment group and the control group.
2. **Increasing tumor cell apoptosis**: The drug - induced cell apoptosis is evaluated by detecting the expression levels of apoptosis - related proteins such as cleaved caspase 3 and ERK phosphorylation, and reducing the expression of the anti - apoptotic protein Bcl - 2.
3. **Reducing the production of inflammatory factors**: The effect of the drug on the inflammatory response is evaluated by detecting the expression levels of inflammation - related cytokines such as IL - 1β, TNF - α and COX - 2.
4. **Inhibiting metastasis - related factors**: The inhibitory effect of the drug on tumor metastasis is evaluated by detecting the expression levels of metastasis - related factors such as CD44, EGFR, TGF - β and VEGF.

The study found that zotarolimus used alone or in combination with 5 - FU can significantly inhibit the growth of HCT - 116 cells, promote cell apoptosis, reduce the production of inflammatory factors, and inhibit the expression of metastasis - related factors. In particular, the combination of zotarolimus and 5 - FU shows a stronger synergistic effect, which can more effectively inhibit tumor growth and promote cell apoptosis, providing a new strategy for the treatment of colon adenocarcinoma.